Left ventricular (LV) hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors. Here, we determined whether aldosterone modulates hypertrophy in HCM. Cardiac and/or plasma aldosterone were measured in organ donors and HCM patients.The effect of the aldosterone synthase (CYP11B2) C-344T polymorphism on LV mass index (LVMI) and interventricular septum thickness (IVS) was determined in 79 genetically independent subjects with HCM. Aldosterone in HCM hearts and plasma was similar to that in normal hearts and plasma. In HCM women, no associations between CYP11B2 genotype and any of the measured parameters were observed, whereas in HCM men, LVMI increased with the presence of the T allele. Similar T allele-related increases were observed for IVS. Multiple regression analysis revealed that the T allelerelated effect on IVS occurred independently of renin, the ACE I/D polymorphism, the AT 1 -receptor A/C 1166 polymorphism and the AT 2 -receptor A/C 3123 polymorphism. In conclusion, circulating and cardiac aldosterone are normal in HCM, thereby arguing against selectively increased cardiac aldosterone production in HCM.Thus, the association between the CYP11B2 C-344T polymorphism and hypertrophy in HCM most likely relates to the T allele-related increases in circulating aldosterone.This finding raises the need for studies determining the benefit of aldosterone blockade in HCM.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterised by unexplained cardiac and myocyte hypertrophy, interstitial fibrosis and myocyte disarray. 1 Mutations in at least 11 different sarcomeric proteins have been identified as the primary defect. 2 Yet, even if patients have identical causative genotypes, they still vary considerably in phenotype. 3 Other factors, genetic as well as environmental, may therefore modify the phenotypic expression of the mutated gene. Angiotensin II (Ang II), the end-product of the renin-angiotensin system (RAS), is among these factors. It modulates cardiac hypertrophy in HCM both via growth-stimulatory Ang II type 1 (AT 1 ) receptors and via growth-inhibitory 4 Ang II type 2 (AT 2 ) receptors. 5, 6 Its effects are gender-specific, and occur independently of the circulating RAS.
A recent study suggests that aldosterone, like Ang II, acts as a major link between sarcomeric mutations and cardiac phenotype in HCM. 7 According to this study, the myocardial aldosterone levels in humans with HCM are fourfold elevated, and aldosterone provokes expression of hypertrophic markers in rat cardiomyocytes and of collagens in rat cardiac fibroblasts. The latter effects occurred in a mineralocorticoid receptor (MR)-dependent manner, as they could be blocked by the MR antagonist spironolactone. 7, 8 MR do occur in the human heart, 9 and aldosterone, like Ang II, 10 may be produced in the heart, particularly in HCM subjects because their cardiac aldosterone synthase (CYP11B2) messenger ribonucleic acid (mRNA) levels are seven-fold increased as compared to age-and gender-matched normal donor hearts. 7 However, aldosterone synthase expression in the heart is six orders below that in the adrenal, 11 and thus cardiac aldosterone production is still controversial. [11] [12] [13] [14] The mere fact that the CYP11B2 C-344T polymorphism associates with left ventricular mass (LVM) 15 may well be explained on the basis of the T allele-related increase in circulating aldosterone levels. [15] [16] [17] [18] [19] It was the aim of the present study to first verify whether the cardiac aldosterone levels are elevated in HCM subjects. Secondly, we investigated the role of aldosterone as a modulator of hypertrophy in HCM, by determining the relationship between the CYP11B2 C-344T polymorphism and cardiac hypertrophy in HCM patients.
Methods

Patients
All studies were approved by the internal review board and patients gave informed consent. Onehundred and seventeen Caucasian patients with HCM (age 21-81 years) visiting the HCM Clinic at the Erasmus MC between 1994 and 1997 for a routine follow-up were included. HCM had been diagnosed on the basis of echocardiographic criteria showing a non-dilated, hypertrophied left , who died of non-cardiac causes (9 cerebrovascular accident, 1 head trauma, 2 brain hypoxia) <24-hours before the heart was taken to the laboratory. Tissue pieces (1-10 g) were kept at -70ºC.
Echocardiographic methods
Two-dimensional echocardiography was performed with commercially available equipment (Toshiba Sonolayer). Images were recorded on videotape for off-line analysis by two physicians who were blinded to the genotyping results. Interventricular septal thickness (IVS) and LVM were determined as described before. 5 LVM was indexed (LVMI) to body surface area (BSA). Peak LV outflow tract gradient at rest was estimated using the modified Bernoulli equation. 5 Since echocardiographic measurement of LVMI may not truly reflect the extent of hypertrophy and the involvement (or lack thereof) of the distal (apical) half of the septum or lateral wall, the extent of hypertrophy was also assessed by a semiquantitative point score (range 0-10) method developed by Wigle et al. 22 Biochemical measurements Prorenin and renin were quantified in peripheral venous blood using an immunoradiometric assay kit (Nichols Institute). 23 Prorenin and renin are expressed as mU/L, using the human kidney renin standard MRC 68/356 as a reference. ACE activity was measured with a commercial kit (ACE Color). 24 Aldosterone was measured by solid-phase radioimmunoassay (DPC) in plasma and LV tissue. To extract aldosterone from cardiac tissue, LV tissue was homogenised 1:2 in methanol. The supernatant was collected after a 15-minute centrifugation at 3,000 rpm at 4ºC, vacuum dried, and dissolved in water. Recovery of 125 I-aldosterone added to cardiac tissue prior to the homogen-ization procedure was >70%, and values were not corrected for incomplete recovery. The detection limit was 25 pg/mL in plasma and 10 pg/g wet weight, and levels below the detection limit were taken to be equal to the detection limit.
Genetic analysis
Peripheral leukocytes were used to isolate genomic DNA in H 2 O using the QIAamp Bloodkit (QIAGEN Inc.). The aldosterone synthase gene (CYP11B2) C-344T polymorphism was determined according to Barbato et al. 16 Polymerase chain reaction (PCR) amplifications were carried out in a 50 μl reaction volume, using 10 ng of genomic DNA. Each reaction contained 1 x PCR buffer II (Perkin Elmer), 1.5 mmol/L MgCl 2 , 0.2 mmol/L each of the deoxynucleotide triphosphates (Roche), 1.25 U of Amplitaq Gold (Perkin Elmer) and 40 pmol each of forward primer 5-CAGGAGGAGACCCCATGTGAC-3 and reverse primer 5-CCTCCACCCTGTTCAGCCC-3'. PCR consisted of initial denaturation at 94°C for 4 minutes followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 67°C for 30 seconds and extension at 72°C for 30 seconds, followed by a final extension at 72°C for 5 minutes. For restriction fragment length polymorphism (RFLP) determination, the PCR product (10 μl) was digested with Hae III for two hours at 37°C. The fragment sizes were analysed on a 4% agarose gel with ethidium bromide staining. The PCR-RFLP was validated by direct sequencing of PCR product from a heterozygote sample, using the Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems) on a ABI 310 capillary sequencer (Applied Biosystems). The ACE I/D polymorphism, the AT 1 -receptor A/C 1166 polymorphism, and the AT 2 -receptor A/C 3123 polymorphism were determined as described before. 5, 6 Statistical analysis Data are expressed as means + SEM or geometric mean and range. Analysis was performed with the SPSS 11.0 statistical package. Hardy-Weinberg equilibrium was tested by X 2 test. Univariate and multiple regression analyses were conducted to determine the percentage of explained variance in LVMI and IVS that is accounted for by the genotypes of the candidate modifier genes and other variables. In the multiple regression analysis the RAS gene polymorphisms, age, peak LV outflow tract gradient and renin concentration were tested as independent variables. Prorenin and ACE were excluded from this analysis because of their high correlations with renin (r=0.68, p<0.001) and ACE genotype (r=0.39, p=0.003), respectively.
Results
Cardiac aldosterone levels in HCM patients (27 (10-233) pg/g, n=8) were not different from the aldosterone levels in hearts of organ donors (26 Table 1 lists the characteristics of the HCM patients by CYP11B2 genotype. Frequencies of the C and T allele (0.41 and 0.59, respectively) were similar to previously reported numbers in normal white populations, [15] [16] [17] and genotype frequencies were in agreement with Hardy-Weinberg equilibrium. The percentage of patients taking ACE-Is, β−adrenergic antagonists, CCB or diuretics did not differ between the various groups (data not shown). When analysing all subjects together, no genotyperelated differences were observed with regard to any of the measured parameters (table 1), in full agreement with a previous study. 25 However, subdivision of the population according to gender ( 
Discussion
The present study shows that aldosterone, like Ang II, is among the factors that modify the phenotypic expression of the mutated gene in HCM. IVS was higher in male HCM subjects carrying the CYP11B2 T allele, and similar observations were made for LVMI and Wigle score. The lack of significance with regard to the latter two parameters relates to the fact that our male population, although large enough to detect a T allele-related increase in IVS of 2 mm or more (power 90%, 5% significance level), was too small to detect significant increases in LVMI and Wigle scores of similar magnitude. To achieve this goal, the patient number should have been three times as large. Thus, given the current population size, the borderline significance of the findings on LVMI and Wigle score can, at most, be interpreted as supportive for the findings on IVS. These authors observed a close relationship between the levels of aldosterone in the heart and in blood plasma, and they concluded that, at least in the rat, cardiac aldosterone is largely, if not completely, of adrenal origin. In fact, the rat heart displayed a large capacity to accumulate circulating aldosterone, allowing blood-derived aldosterone to reach cardiac tissue levels that are up to 10 times higher than the aldosterone levels in blood. 13, 14 The plasma levels of aldosterone in subjects with HCM, like those of renin, are in the (low) normal range (~30-200 pg/ml), 7, 26, 27 both in this study and a previous study, 7 and thus no alteration in the cardiac aldosterone content of HCM subjects would be expected if cardiac aldosterone were exclusively of adrenal origin. Based on cardiac CYP11B2 messenger ribonucleic acid measurements however, Tsybouleva et al. 7 have suggested that cardiac aldosterone is of local origin. In contrast with this conclusion, their cardiac aldosterone levels were < 0.1 pg/g protein, i.e. > 2 orders of magnitude below the levels that are minimally expected based on the presence of blood in cardiac tissue. 28, 29 Thus, conclusive evidence for cardiac production of aldosterone in subjects with HCM is lacking. Future studies should further investigate this issue, also taking into consideration the morphology of HCM and whether the hypertrophy obstructs output flow or not.
The association between CYP11B2 genotype and cardiac hypertrophy in HCM parallels the association between the CYP11B2 T allele and LVM in subjects with essential hypertension. 15 It also extends a previous study on this polymorphism in HCM subjects which showed no significant T allele-related increase in LVMI. 25 The latter study did not evaluate the gender-specificity of the effect. In addition, since the influence of the CYP11B2 genotype, like that of the ACE I/D genotype, will depend on the gene mutation that determines the primary defect, 30 CYP11B2 T allelerelated effects do not necessarily apply to all HCM populations.
According to most [15] [16] [17] [18] [19] (but not all) 17 ,31 studies, the CYP11B2 T allele is associated with elevated plasma aldosterone levels, while serum aldosterone associates with the variability of LVM in both healthy controls and subjects with hypertension. 32 Thus, a picture arises in which the T allele results in elevated plasma levels of aldosterone, which subsequently affect cardiac hypertrophy, not only in subjects with essential hypertension, 32 but also in subjects with HCM. Indeed, there is ample evidence suggesting that circulating aldosterone acts as a pro-inflammatory, hypertrophic and profibrotic factor in the heart. [7] [8] [33] [34] In further support of this concept, MR occur in the human heart 9 and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity associates directly with LVM in essential hypertension. 35 11β-HSD2 inactivates cortisol and corticosterone, thereby preventing these glucocorticoids from stimulating MR. The 11β-HSD2 levels are relatively low in the heart, 9 whereas the glucocorticoid concentrations in blood are several orders of magnitude above those of aldosterone. Thus, activation of cardiac MR by circulating aldosterone is possible only in the presence of sufficiently high 11 β-HSD2 activity. Importantly, the above scenario does not require the cardiac aldosterone levels to be elevated in HCM subjects as compared to controls, since the genotype distribution in our HCM population was similar to that in normal white populations. [15] [16] [17] Two independent investigations have recently shown that the CYP11B2 C-344T polymorphism is in strong linkage disequilibrium with polymorphisms of the nearby CYP11B1 gene. 36, 37 Since the latter polymorphisms predict activity of the cortisol-producing enzyme 11β-hydroxylase, an alternative explanation of our findings is that reduced 11β-hydroxylase activity rather than increased aldosterone levels underlies the T allelerelated cardiac hypertrophy. 38 Future studies, involving aldosterone, 11-deoxycortisol and cortisol measurements in serum and/or urine of HCM subjects, 39 should address this possibility.
The effect of the T allele on cardiac hypertrophy occurred independently of circulating renin, the ACE gene I/D polymorphism, the AT 1 -receptor gene A/C 1166 polymorphism and the AT 2 -receptor A/C 3123 polymorphism. Since both AT 1 -and AT 2receptors modulate cardiac hypertrophy in HCM, most likely in an opposite manner, 5, 6 it appears that aldosterone exerts additive effects on top of Ang II, 8 despite earlier studies suggesting that aldosterone exerts its effects via Ang II or AT 1receptors and vice versa. [40] [41] [42] This conclusion is in full agreement with the renin-independent associations between LVM, CYP11B2 genotype and 11β-HSD2 activity in hypertension. 15, 35 The genderspecificity of the association in our study is more difficult to explain, and, given the low number of CC women, should be interpreted with care. In particular, the apparently opposite findings in women as compared to men (i.e., IVS, LVMI and Wigle score being higher in CC women vs. CT+TT women) are due to one CC woman with an exceptionally large heart. Without this woman the findings in women would have been identical to those in men. Nevertheless, gender-related differences might occur. For instance, estrogen may mimic or antagonise some of the effects of aldosterone, 43 whereas the well-known genderrelated differences in renin and angiotensinogen 27, 44 will affect, through Ang II, the biosynthesis of aldosterone.
Conclusion
The levels of aldosterone in heart and blood plasma of HCM subjects are in the low normal range, thereby arguing against the concept of selectively increased cardiac aldosterone production in HCM. This does not exclude the possibility that aldosterone modulates cardiac hypertrophy in HCM. In fact, the CYP11B2 T allele-related increase in cardiac hypertrophy in HCM subjects fully parallels similar observations in subjects with hypertension, and the simplest explanation of these observations is that they are related to the elevated circulating aldosterone levels in T allele carriers, both in hypertension and HCM. Interestingly in this regard, the MR antagonist spironolactone was found to reduce the extent of myocyte disarray and to reverse interstitial fibrosis in a transgenic mouse model of human HCM mutation (cTnT-Q92 mice), despite the fact that these mice did not display elevated cardiac aldosterone levels. 7 Combined with the results from the present study, these data raise the need for studies determining the benefit of MR blockade in HCM. 
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